In 2022, the size of the cellular health screening market amounted to USD 2,622.1 million and is projected to rise at a compound annual growth rate of 9.7% until 2030 when it reaches USD 5,512.8 million.
This growth of the market can be credited to the increasing applications of cellular health screening in modified drugs, sensing illnesses at an initial stage, aiding preventive care, and spotting different health-linked issues; the growing count of awareness campaigns; the rising acceptance of telomere performance programs; and the rising occurrence of chronic diseases primarily cancer throughout the globe.
On the basis of test type, the single-test panel category is dominating the industry. This can be credited to its labor productivity, cost-efficiency, and augmented potential for automation.
Among single-panel tests, the need for telomere single-panel tests is projected to advance at the highest rate during the projection period. This can be because these provide precise data, help in calculating the length of telomere, and support in determining cell age.
On the basis of sample type, the urine sample category is estimated to witness the fastest development during the projection period. This is mainly because is it extensively utilized for sensing and handling a huge count of syndromes, like diabetes, kidney diseases, and urinary tract infections.
Furthermore, gathering urine is a convenient and non-invasive technique and it can be done by patients and does not need any equipment or specialist. Furthermore, a urine sample is also utilized for the identification of heavy metals and oxidative stress and cell health studies.
On the basis of the collection site, the hospital’s category grips the largest income share in the industry. This is mainly because of the growing healthcare spending and the existence of a huge count of hospitals throughout the globe, where analysis and treatments are offered instantaneously, and they have progressive diagnostic methods and medicinal specialists for specific tests for the identification of illnesses.
The North American market will continue to hold the world’s top position in cell health screening, valued at USD 2.5 billion by 2030. In the region, this is due to increasing government funding for preventative health care, rapid adoption of new technologies, rising awareness of personalized medicine, and an increased incidence of chronic diseases such as tuberculosis.
In North America, the U.S. industry grips the dominating position, and it will advance at a CAGR of 10% during the projection period. This can be credited to the strong healthcare infrastructure and the presence of a huge count of key companies in the nation.
The key drivers of the cellular health screening industry comprise the growing emphasis on healthy life expectancy, increasing healthcare spending, the rising occurrence of illnesses, and the rising elderly populace.